Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PTCT stock price vs V: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at V's multiple
Needs V P/E.
Implied fair value · at PTCT's multiple
Needs PTCT P/E.
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency edge
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: PTCT FY 2025 (ended Dec 31, 2025) · V FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
-$676.41M
Price / tangible book
—
Price / book
—
Return on equity
-332.5%
Return on assets
23.5%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity
-$9.62B
Price / tangible book
—
Price / book
—
Return on equity
52.9%
Return on assets
20.1%
Efficiency ratio
—
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
PTC Therapeutics, Inc. · implied price per share
Bear
$79.76
Base
$93.84
Bull
$107.91
VISA INC. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-2.79x
0.66x
Net debt / EBITDA
Leverage against operating earnings
-1.83x
0.18x
Cash and equivalents
Liquid reserves on the balance sheet
$1.95B
$20.61B
Total debt
Interest-bearing obligations outstanding
$572.04M
$25.17B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
PTCT vs VRTX
Sarepta Therapeutics, Inc.
PTCT vs SRPT
BIOMARIN PHARMACEUTICAL INC
PTCT vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
PTCT vs ALNY
Mastercard Incorporated
PTCT vs MA
PayPal Holdings, Inc.
PTCT vs PYPL
American Express Company
PTCT vs AXP
Block, Inc.
PTCT vs SQ
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Price unavailable
